{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:39:01Z","timestamp":1776944341538,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["patient-research.elsevier.com","nutritionjrnl.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.nut.2013.12.005","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T19:00:11Z","timestamp":1387047611000},"page":"1069-1075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia"],"prefix":"10.1016","volume":"30","author":[{"given":"Katja","family":"Trobec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Palus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anika","family":"Tschirner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Doehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitja","family":"Lainscak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Springer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nut.2013.12.005_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.nut.2013.12.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","article-title":"Cachexia as a major underestimated and unmet medical need: Facts and numbers","volume":"1","author":"von Haehling","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.nut.2013.12.005_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00520-012-1697-z","article-title":"Diagnostic criteria of cancer cachexia: Relation to quality of life, exercise capacity and survival in unselected palliative care patients","volume":"21","author":"Wallengren","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.nut.2013.12.005_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13539-011-0051-5","article-title":"The role of insulin resistance in the development of muscle wasting during cancer cachexia","volume":"3","author":"Honors","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.nut.2013.12.005_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13539-011-0043-5","article-title":"Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia","volume":"2","author":"Trobec","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.nut.2013.12.005_bib6","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1210\/en.2006-0251","article-title":"Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling","volume":"147","author":"Wang","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.nut.2013.12.005_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MCO.0b013e32833862df","article-title":"Signaling pathways perturbing muscle mass","volume":"13","author":"Glass","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.nut.2013.12.005_bib8","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nut.2013.12.005_bib9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.nut.2013.12.005_bib10","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.2337\/dc11-1032","article-title":"Insulin sensitizers may attenuate lean mass loss in older men with diabetes","volume":"34","author":"Lee","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nut.2013.12.005_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ijc.24784","article-title":"Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice","volume":"126","author":"Asp","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nut.2013.12.005_bib12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4161\/cbt.12.11.18134","article-title":"Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia","volume":"12","author":"Asp","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.nut.2013.12.005_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.nut.2013.12.005_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nut.2013.12.005_bib15","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2006.10.077","article-title":"A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure","volume":"49","author":"Dargie","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nut.2013.12.005_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yjmcc.2009.04.011","article-title":"Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation","volume":"47","author":"Festuccia","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.nut.2013.12.005_bib17","first-page":"347","article-title":"Cardiac alterations in cancer-induced cachexia in mice","volume":"37","author":"Tian","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.nut.2013.12.005_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s13539-011-0029-3","article-title":"IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia","volume":"2","author":"Schmidt","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.nut.2013.12.005_bib19","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/ijc.27494","article-title":"Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia","volume":"131","author":"Springer","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nut.2013.12.005_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijcard.2008.06.094","article-title":"No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure","volume":"137","author":"Akashi","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.nut.2013.12.005_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s004230100206","article-title":"Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxis","volume":"386","author":"Bauhofer","year":"2001","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.nut.2013.12.005_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/JOE-12-0307","article-title":"Heterogeneous time-dependent response of adipose tissue during the development of cancer cachexia","volume":"215","author":"Batista","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.nut.2013.12.005_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/01635580903441220","article-title":"Evidence for a novel serum factor distinct from zinc alpha-2 glycoprotein that promotes body fat loss early in the development of cachexia","volume":"62","author":"Byerley","year":"2010","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.nut.2013.12.005_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clnu.2006.09.009","article-title":"Fat loss in cachexia\u2014is there a role for adipocyte lipolysis?","volume":"26","author":"Ryd\u00e9n","year":"2007","journal-title":"Clin Nutr"},{"key":"10.1016\/j.nut.2013.12.005_bib25","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s00125-006-0336-y","article-title":"PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control","volume":"49","author":"Festuccia","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.nut.2013.12.005_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/diabetes.52.2.283","article-title":"Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects","volume":"52","author":"Virtanen","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.nut.2013.12.005_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1464-5491.2009.02897.x","article-title":"The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with type 2 diabetes","volume":"27","author":"Nam","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.nut.2013.12.005_bib28","doi-asserted-by":"crossref","first-page":"e24650","DOI":"10.1371\/journal.pone.0024650","article-title":"The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min\/+) mouse","volume":"6","author":"White","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nut.2013.12.005_bib29","first-page":"1321","article-title":"Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice","volume":"39","author":"Tian","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.nut.2013.12.005_bib30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.lfs.2010.12.010","article-title":"Myocardial dysfunction in an animal model of cancer cachexia","volume":"88","author":"Xu","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.nut.2013.12.005_bib31","doi-asserted-by":"crossref","first-page":"159415","DOI":"10.1155\/2008\/159415","article-title":"Clinical use of PPARgamma ligands in cancer","volume":"2008","author":"Hatton","year":"2008","journal-title":"PPAR Res"},{"key":"10.1016\/j.nut.2013.12.005_bib32","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1517\/13543784.12.12.1925","article-title":"Therapeutic potential of thiazolidinediones as anticancer agents","volume":"12","author":"Panigrahy","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.nut.2013.12.005_bib33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ejca.2007.05.005","article-title":"The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver","volume":"43","author":"Borbath","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nut.2013.12.005_bib34","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/bjc.2012.130","article-title":"PPARgamma inhibits hepatocellular carcinoma metastases in\u00a0vitro and in mice","volume":"106","author":"Shen","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nut.2013.12.005_bib35","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/ijc.23765","article-title":"Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers","volume":"123","author":"Lubet","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nut.2013.12.005_bib36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.26259","article-title":"Decreased risk of liver cancer with thiazolidinediones therapy in patients with type 2 diabetes: Results from a meta-analysis","volume":"58","author":"Wang","year":"2013","journal-title":"Hepatology"}],"container-title":["Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089990071300556X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089990071300556X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T06:21:11Z","timestamp":1538979671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089990071300556X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S089990071300556X"],"URL":"https:\/\/doi.org\/10.1016\/j.nut.2013.12.005","relation":{},"ISSN":["0899-9007"],"issn-type":[{"value":"0899-9007","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia","name":"articletitle","label":"Article Title"},{"value":"Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nut.2013.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}